Abstract: Provided herein are multicyclic compounds of formula (IVa), shown below, wherein R1, R2, R3, R4, R5, R6, R7, m, and n are defined herein elsewhere, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

Abstract: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

Abstract: A working method of a smart key device, in which it includes: power on the smart key device; the smart key device reads Bluetooth module parameters, and determines whether the Bluetooth module parameters are read successfully, if the parameters are read successfully, switch the Bluetooth module to connection state, and execute a next step; if the parameters are not read successfully, execute the next step directly; the smart key device determines whether working voltage is lower than a preset value, if yes, prompt low voltage state, and the device is turned off after a first preset time; if no, the device tests working voltage and waits for an interrupt trigger signal; when the device receives the interrupt trigger signal, enter corresponding interruption according to the interrupt trigger signal, after execute corresponding interrupt processing, exit corresponding interruption and continue to test the working voltage.

Abstract: The present invention relates to a self-deodorizing composting system, comprising an outer membrane, an inner membrane, an air-ribbed cage and a deodorizing base, wherein two deodorizing bases are provided; the outer membrane and the inner membrane are held by the air-ribbed cage, with both ends of the outer membrane and the inner membrane respectively fixed to the two deodorizing bases, whereby a closed space is formed between the outer membrane and the inner membrane; the inner side of the inner membrane is used for placing the composting piles, with the malodor and water vapor generated from the composting piles entering into the closed space formed between the outer membrane and the inner membrane through the inner membrane, so that the water vapor is condensed into the water in the closed space, and the malodor molecules are absorbed and dissolved into the condensed water, thus forming the waste water which falls along the inner side of the outer membrane and the outer side of the inner membrane to the b

Abstract: Phenyl-substituted cyclohexylamine derivatives and methods for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.

Abstract: The present invention relates to a method for inhibiting the formation of dioxin-like compounds in solid waste incineration flue gases, belonging to the field of cleaning of solid waste incineration flue gases. In accordance with the present invention, when incineration flue gases cool down to 500˜450° C., the flue gases are introduced into an inhibition reactor where copper chlorides in flue gas particulates mix and react with inhibitors to convert into copper metaphosphate so as to inactivate the copper chlorides which can catalyze the formation of dioxin-like compounds and control dioxin-like compound pollutants in incineration flue gases at the source. Compared with the prior art, the invention can effectively control the main formation ways of dioxin-like compounds in solid waste incineration flue gases by optimizing inhibitors and reaction conditions.

Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.

Abstract: The present invention discloses a method and a system of treating biomass wastes by biochemistry-thermochemistry multi-point interconnection. The present invention applies solid, gas and liquid products of the thermochemical treatment subsystem to the biochemical treatment subsystem and applies heat produced by the biochemical treatment subsystem to the thermochemical treatment subsystem, forming multi-point and two-way interconnection between the biochemical treatment subsystem and the thermochemical treatment subsystem, thereby increasing the yield and stability of energy gas of the biochemical treatment subsystem and reducing pollution and energy consumption of the thermochemical treatment subsystem respectively. The present invention is suitable for treating biomass wastes with high and low water contents at the same time, producing soil amendment, liquid fuel and biogas, having properties of low secondary pollution and significant reduction of greenhouse gas emission and so on.

Abstract: In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. For example, disclosed herein are compounds having formula (IIa) shown below, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the variables are defined herein. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Abstract: In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Abstract: A working method of a smart key device, in which it includes: power on the smart key device; the smart key device reads Bluetooth module parameters, and determines whether the Bluetooth module parameters are read successfully, if the parameters are read successfully, switch the Bluetooth module to connection state, and execute a next step; if the parameters are not read successfully, execute the next step directly; the smart key device determines whether working voltage is lower than a preset value, if yes, prompt low voltage state, and the device is turned off after a first preset time; if no, the device tests working voltage and waits for an interrupt trigger signal; when the device receives the interrupt trigger signal, enter corresponding interruption according to the interrupt trigger signal, after execute corresponding interrupt processing, exit corresponding interruption and continue to test the working voltage.

Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

Abstract: In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.